Aptus Pharma enters into Urology therapy segment

24 Nov 2025 Evaluate

Aptus Pharma has entered into the Urology therapy segment as part of its ongoing business expansion initiatives. The company will soon be launching a new portfolio of products in this segment, including Silodosin range, Tamsulosin range and Alkalizer formulations. 

The introduction of these products is supported by the company’s strong field-sales force and a robust distribution network consisting of 150+ PLS distributors and sub-distributors across India. This new portfolio is expected to contribute significantly to the company’s future revenue growth and profitability. 

Aptus Pharma is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. While the company does not own any manufacturing facilities, it operates through a contract manufacturing model.


Aptus Pharma Share Price

169.85 1.85 (1.10%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Redington 268.45
Adani Enterprises 2215.10
Amrapali Industries 14.29
Rashi Peripheral 354.00
PDS 371.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×